PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15582680-5 2004 Brain tissues were collected at PD 70 for determination of radiolabeled paroxetine binding to the serotonin transporter (SERT) in the neocortex and hippocampus. Paroxetine 72-82 solute carrier family 6 member 4 Rattus norvegicus 98-119 16448580-5 2007 In-vitro binding studies showed that R-citalopram attenuated the association rates of escitalopram and paroxetine to the 5-HT transporter, but had no effect on the association rates of fluoxetine, venlafaxine or sertraline. Paroxetine 103-113 solute carrier family 6 member 4 Rattus norvegicus 121-137 16448580-12 2007 In conclusion, the present in-vitro and in-vivo studies show that R-citalopram counteracts the activity of escitalopram and paroxetine, but not fluoxetine, by acting at the allosteric binding site of the 5-HT transporter, either located in the dorsal raphe nucleus or post-synaptically in the ventral hippocampus. Paroxetine 124-134 solute carrier family 6 member 4 Rattus norvegicus 204-220 16341932-1 2005 The binding of labelled paroxetine to the serotonin transporter (SERT) of platelet membranes has been studied in both venous and mixed venous/arterial blood of the rat. Paroxetine 24-34 solute carrier family 6 member 4 Rattus norvegicus 42-63 16341932-1 2005 The binding of labelled paroxetine to the serotonin transporter (SERT) of platelet membranes has been studied in both venous and mixed venous/arterial blood of the rat. Paroxetine 24-34 solute carrier family 6 member 4 Rattus norvegicus 65-69 16341932-2 2005 In addition, we studied the inhibition of paroxetine binding to SERT by quipazine and N-methyl-quipazine (NMQ). Paroxetine 42-52 solute carrier family 6 member 4 Rattus norvegicus 64-68 15715667-7 2005 This effect may be (at least in part) related to a greater down-regulation of hippocampal serotonin transporter binding sites by paroxetine in HABs compared with LABs, while 5-HT1A receptor expression remained unaffected in this brain area. Paroxetine 129-139 solute carrier family 6 member 4 Rattus norvegicus 90-111 18437564-0 2008 In vivo effect of antidepressants on [3H]paroxetine binding to serotonin transporters in rat brain. Paroxetine 37-51 solute carrier family 6 member 4 Rattus norvegicus 63-85 18437564-6 2008 Density of SERT was measured in cortex and hippocampus using [(3)H]paroxetine (0.03-1.0 nM) in presence and absence of 10 muM fluoxetine as displacer. Paroxetine 67-77 solute carrier family 6 member 4 Rattus norvegicus 11-15 18022203-7 2007 These data suggest that, at the concentrations employed, fluoxetine inhibits serotonin uptake at both DAT and SERT, whereas paroxetine only inhibits serotonin uptake at SERT. Paroxetine 124-134 solute carrier family 6 member 4 Rattus norvegicus 169-173 17657807-5 2007 [3H]-(S)-Citalopram and [3H]-(+)-McN5652 display statistically significantly lower affinity, whereas [3H]paroxetine displays statistically significantly higher affinity for SERT in monkey cortex when compared with the rat cerebrum. Paroxetine 105-115 solute carrier family 6 member 4 Rattus norvegicus 173-177 15582680-5 2004 Brain tissues were collected at PD 70 for determination of radiolabeled paroxetine binding to the serotonin transporter (SERT) in the neocortex and hippocampus. Paroxetine 72-82 solute carrier family 6 member 4 Rattus norvegicus 121-125 14568333-3 2003 The goal of this experiment was to determine how aging and estrogen interact to regulate SERT levels in the forebrain of young and reproductively senescent female Sprague-Dawley rats using [3H]paroxetine. Paroxetine 193-203 solute carrier family 6 member 4 Rattus norvegicus 89-93 15034919-7 2004 The higher in vivo binding of [125I]ADAM in pCPA-treated rats than in controls was mainly due to an increase in specific binding to the SERT, as demonstrated by greatly reduced binding in the presence of a saturating dose of paroxetine. Paroxetine 225-235 solute carrier family 6 member 4 Rattus norvegicus 136-140 14515339-16 2003 SERT inhibitors (sertraline, paroxetine, citalopram, and fluoxetine) also increased PKC activity. Paroxetine 29-39 solute carrier family 6 member 4 Rattus norvegicus 0-4 10773546-1 2000 The serotonin transporters (SERT) are the primary binding sites for selective serotonin reuptake inhibitors, commonly used antidepressants such as fluoxetine, sertraline, and paroxetine. Paroxetine 175-185 solute carrier family 6 member 4 Rattus norvegicus 4-26 12429568-4 2002 Perinatal development of SERT was visualized and quantified using [(3)H]-paroxetine binding autoradiography in embryonic and neonatal rat brain from embryonic day 15 (E15) to postnatal day p30 (p30). Paroxetine 73-83 solute carrier family 6 member 4 Rattus norvegicus 25-29 12024106-3 2002 These mitogenic and comitogenic effects require 5-HT internalization by the high-affinity 5-HTT, which can be competitively inhibited by specific drugs such as fluoxetine and paroxetine. Paroxetine 175-185 solute carrier family 6 member 4 Rattus norvegicus 90-95 12581167-3 2003 Midbrain and hippocampal [3H]paroxetine binding at the 5-HTT and hippocampal [3H]serotonin (5-HT) reuptake were increased in male and female F344 rats, compared to their LEW counterparts, these strain differences being observed both in rats of commercial origin and in homebred rats. Paroxetine 29-39 solute carrier family 6 member 4 Rattus norvegicus 55-60 12581167-5 2003 Saturation studies of midbrain and hippocampal [3H]paroxetine binding at the 5-HTT, and hippocampal and blood platelet [3H]5-HT reuptake, also revealed significant strain differences in Bmax and Vmax values. Paroxetine 51-61 solute carrier family 6 member 4 Rattus norvegicus 77-82 11044887-4 2000 Moreover, the specific hypothalamic uptake was blocked by pretreatment with SERT selective competing drugs, such as paroxetine and (+)McN5652, while other noncompeting drugs, such as ketanserin, raclopride, and methylphenidate, showed no effect. Paroxetine 116-126 solute carrier family 6 member 4 Rattus norvegicus 76-80 10812044-2 2000 The antidepressant paroxetine is believed to produce its therapeutic effects primarily by acting as a highly selective antagonist of the serotonin transporter (SERT). Paroxetine 19-29 solute carrier family 6 member 4 Rattus norvegicus 137-158 10812044-2 2000 The antidepressant paroxetine is believed to produce its therapeutic effects primarily by acting as a highly selective antagonist of the serotonin transporter (SERT). Paroxetine 19-29 solute carrier family 6 member 4 Rattus norvegicus 160-164 10812044-9 2000 CONCLUSIONS: Although paroxetine is a very potent inhibitor of the SERT, paroxetine also inhibits the NET at serum concentrations > 100 ng/mL. Paroxetine 22-32 solute carrier family 6 member 4 Rattus norvegicus 67-71 10773546-1 2000 The serotonin transporters (SERT) are the primary binding sites for selective serotonin reuptake inhibitors, commonly used antidepressants such as fluoxetine, sertraline, and paroxetine. Paroxetine 175-185 solute carrier family 6 member 4 Rattus norvegicus 28-32 9878762-5 1999 The density of SERT sites, assessed by autoradiography of [3H]paroxetine binding, was significantly reduced in arcuate nucleus and median raphe after castration, and increased in arcuate, basolateral amygdala and ventromedial hypothalamic nucleus by treatment with EB or TP, but not 5alpha-DHT. Paroxetine 58-72 solute carrier family 6 member 4 Rattus norvegicus 15-19 10024307-4 1999 This effect was dependent on the 5-HT transporter (5-HTT), since it was prevented by the 5-HTT inhibitors fluoxetine (10(-6) mol/L) and paroxetine (10(-7) mol/L), but it was unaltered by ketanserin (10(-6) mol/L), a 5-HT2A receptor antagonist. Paroxetine 136-146 solute carrier family 6 member 4 Rattus norvegicus 33-49 10024307-4 1999 This effect was dependent on the 5-HT transporter (5-HTT), since it was prevented by the 5-HTT inhibitors fluoxetine (10(-6) mol/L) and paroxetine (10(-7) mol/L), but it was unaltered by ketanserin (10(-6) mol/L), a 5-HT2A receptor antagonist. Paroxetine 136-146 solute carrier family 6 member 4 Rattus norvegicus 51-56 10024307-4 1999 This effect was dependent on the 5-HT transporter (5-HTT), since it was prevented by the 5-HTT inhibitors fluoxetine (10(-6) mol/L) and paroxetine (10(-7) mol/L), but it was unaltered by ketanserin (10(-6) mol/L), a 5-HT2A receptor antagonist. Paroxetine 136-146 solute carrier family 6 member 4 Rattus norvegicus 89-94 9780082-2 1998 Binding of [3H]GBR-12935 (to DAT) and [3H]paroxetine (to 5-HTT) increased steadily and very similarly, from low levels at PD-7 to maximal levels, to 6-7-fold higher density at PD-60 in both regions. Paroxetine 42-52 solute carrier family 6 member 4 Rattus norvegicus 57-62 9283827-6 1997 Tissue 5-HT recovery was dose-dependently inhibited by the concurrent perfusion of citalopram, fluoxetine and paroxetine, showing that it essentially measured uptake through the high-affinity 5-HT transporter. Paroxetine 110-120 solute carrier family 6 member 4 Rattus norvegicus 192-208 9669506-2 1998 The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter. Paroxetine 39-49 solute carrier family 6 member 4 Rattus norvegicus 111-127 9489728-5 1998 Autoradiography using [3H]paroxetine revealed highest 5-HT transporter binding densities in the regions in which voltammetric measurements were made. Paroxetine 22-36 solute carrier family 6 member 4 Rattus norvegicus 54-70 9542725-7 1998 The binding of [3H]paroxetine, a marker of serotonin transporter, was reduced in the retina of both species after the central treatment with the neurotoxic substance. Paroxetine 15-29 solute carrier family 6 member 4 Rattus norvegicus 43-64 9481808-1 1997 [3H]Paroxetine binding to the serotonin transporter has been shown to be altered in brain tissue from schizophrenic subjects. Paroxetine 4-14 solute carrier family 6 member 4 Rattus norvegicus 30-51 9285352-4 1997 The effect of the selective serotonin reuptake inhibitor paroxetine on neuronal expression of the serotonin transporter mRNA was examined. Paroxetine 57-67 solute carrier family 6 member 4 Rattus norvegicus 98-119 8364729-4 1993 [3H]paroxetine-binding to serotonin transporter sites was decreased by tianeptine treatment as well as by imipramine in both hippocampus and cerebral cortex, with some overlap of the fields that were significantly affected, whereas there were no effects of stress per se and no evidence of a stress x drug interaction. Paroxetine 4-14 solute carrier family 6 member 4 Rattus norvegicus 26-47 7925606-2 1994 Tianeptine (10 mg/kg twice daily, for 14 days) significantly reduced both the expression of serotonin transporter mRNA and serotonin transporter binding sites labeled by [3H]paroxetine in rat dorsal raphe nucleus. Paroxetine 170-184 solute carrier family 6 member 4 Rattus norvegicus 123-144 7509861-4 1994 Radioautography with 3H-imipramine or 3H-paroxetine (another marker for the transporter) confirmed that the 5-HT transporter is present in the cerebral cortex when it contains serotonergic growth cones, but not serotonergic synapses. Paroxetine 38-51 solute carrier family 6 member 4 Rattus norvegicus 108-124 8883942-7 1996 Paroxetine binding to the 5-HTT protein in frontal cortex was, as expected, reduced in all of the treated groups relative to vehicle controls. Paroxetine 0-10 solute carrier family 6 member 4 Rattus norvegicus 26-31 7539115-3 1994 The binding of [3H]paroxetine to the presynaptic 5-HT transporter was decreased and high affinity uptake of [3H]5-HT was reduced by a similar amount, indicating neurodegeneration of 5-HT terminals. Paroxetine 15-29 solute carrier family 6 member 4 Rattus norvegicus 49-65 8364729-6 1993 Whereas the actions of imipramine and tianeptine on 5-HT2 and 5-HT1A receptors are specific to each drug, the surprising finding of a similar effect of both drugs to reduce serotonin transporter sites labelled by [3H]paroxetine suggest the possibility of a common action for these two drugs in spite of their opposite effects on serotonin re-uptake. Paroxetine 217-227 solute carrier family 6 member 4 Rattus norvegicus 173-194 1836639-0 1991 Platelet 3H-paroxetine binding to the serotonin transporter is insensitive to changes in central serotonergic innervation in the rat. Paroxetine 9-22 solute carrier family 6 member 4 Rattus norvegicus 38-59 1477953-3 1992 To study the mechanism of this effect we measured the 5-HT transporter or uptake site, a presynaptic marker, using [3H]paroxetine binding. Paroxetine 119-129 solute carrier family 6 member 4 Rattus norvegicus 54-70 1402927-1 1992 The sodium dependence of binding of [3H]-paroxetine, a selective serotonin uptake inhibitor, to the serotonin transporter in rat diencephalon was studied in both brain membranes and tissue sections and compared with that of 5-[3H]hydroxytryptamine ([3H]5-HT) uptake by synaptosomes from the same region. Paroxetine 41-51 solute carrier family 6 member 4 Rattus norvegicus 100-121 1400397-12 1992 [3H]Paroxetine, a potent and selective 5-HT uptake inhibitor, was used to label the 5-HT transporter. Paroxetine 0-14 solute carrier family 6 member 4 Rattus norvegicus 84-100 1836639-1 1991 The serotonin transporter labeled in platelets by 3H-imipramine or 3H-paroxetine binding has been suggested to be a peripheral marker for changes in serotonin uptake in the brain that may be related to depression. Paroxetine 67-80 solute carrier family 6 member 4 Rattus norvegicus 4-25 30096380-2 2018 Inhibitors of SERT binding are well known as selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, paroxetine, and escitalopram, that are commonly prescribed antidepressants. Paroxetine 125-135 solute carrier family 6 member 4 Rattus norvegicus 14-18 2147655-0 1990 Inhibitory and regulatory binding sites on the rat brain serotonin transporter: molecular weight of the [3H]paroxetine and [3H]citalopram binding proteins. Paroxetine 108-118 solute carrier family 6 member 4 Rattus norvegicus 57-78 1980843-1 1990 The present study sought to determine whether [3H]paroxetine, a potent and selective inhibitor of serotonin uptake in vitro, could be used to label the serotonin transporter in the rat brain in vivo such that it might be employed to develop a presynaptic serotonergic positron emission tomography ligand. Paroxetine 46-60 solute carrier family 6 member 4 Rattus norvegicus 152-173 2143567-1 1990 The effects of halothane and ketamine on (1) serotonin (5-hydroxytryptamine; 5-HT) uptake and (2) paroxetine binding to the 5-HT transporter in neuronal membranes were determined in rat brain. Paroxetine 98-108 solute carrier family 6 member 4 Rattus norvegicus 124-140 2143567-2 1990 Both anesthetics inhibited the uptake of [3H]5-HT by synaptosomes, but only ketamine affected binding of [3H]paroxetine to the 5-HT transporter. Paroxetine 105-119 solute carrier family 6 member 4 Rattus norvegicus 127-143 33908307-12 2021 tDCS-paroxetine co-treatment had variable effects on 5-HT1A receptors and SERT mRNA. Paroxetine 5-15 solute carrier family 6 member 4 Rattus norvegicus 74-78 33908307-14 2021 CONCLUSION: These findings point towards potential synergistic efficacies of tDCS and paroxetine in the OBX model of adolescent depression via mechanisms associated with altered expression of BDNF, 5-HT1A, SERT and zif268 in discrete corticolimbic areas. Paroxetine 86-96 solute carrier family 6 member 4 Rattus norvegicus 206-210 20072118-2 2010 We have recently found that lesions to the rat orbitofrontal cortex (OFC) led to an increase in compulsive lever-pressing that was prevented by systemic administration of the selective serotonin reuptake inhibitor paroxetine, and paralleled by an increase in the density of the striatal serotonin transporter. Paroxetine 214-224 solute carrier family 6 member 4 Rattus norvegicus 287-308 28983622-1 2017 The aim of the present study was to investigate the role of paroxetine intervention in epilepsy, and its association with the expression of serotonin transporter (SERT) and hippocampal apoptosis. Paroxetine 60-70 solute carrier family 6 member 4 Rattus norvegicus 140-161 28983622-1 2017 The aim of the present study was to investigate the role of paroxetine intervention in epilepsy, and its association with the expression of serotonin transporter (SERT) and hippocampal apoptosis. Paroxetine 60-70 solute carrier family 6 member 4 Rattus norvegicus 163-167 28983622-15 2017 Following paroxetine administration, SERT expression was decreased in the raphe nucleus and increased in the hippocampus. Paroxetine 10-20 solute carrier family 6 member 4 Rattus norvegicus 37-41